SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-21-062387
Filing Date
2021-05-06
Accepted
2021-05-06 16:06:04
Documents
59
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tm2111288d1_10q.htm 10-Q 438132
2 EXHIBIT 31.1 tm2111288d1_ex31-1.htm EX-31.1 11186
3 EXHIBIT 31.2 tm2111288d1_ex31-2.htm EX-31.2 11048
4 EXHIBIT 32.1 tm2111288d1_ex32-1.htm EX-32.1 5105
  Complete submission text file 0001104659-21-062387.txt   4424435

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cldx-20210331.xml EX-101.INS 1278844
6 XBRL TAXONOMY EXTENSION SCHEMA cldx-20210331.xsd EX-101.SCH 27809
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cldx-20210331_cal.xml EX-101.CAL 41507
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cldx-20210331_def.xml EX-101.DEF 104839
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20210331_lab.xml EX-101.LAB 323244
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20210331_pre.xml EX-101.PRE 233763
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 21897700
SIC: 2835 In Vitro & In Vivo Diagnostic Substances